Related Experiment Video

Updated: Oct 8, 2025

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.7K

TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance

Yoelsis Garcia-Mayea1, Cristina Mir1, Laia Carballo1

  • 1Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Biochimica Et Biophysica Acta. Reviews on Cancer
|January 3, 2022
PubMed

Insights

Tetraspanin 1 (TSPAN1) plays a key role in cancer progression and chemotherapy resistance. Targeting TSPAN1 may offer new strategies for anticancer therapies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Tetraspanins (TSPANs) are membrane receptors involved in cell signaling and protein anchoring.
  • Increasing evidence links TSPANs to cancer development and progression.
  • Tetraspanin 1 (TSPAN1) is implicated in tumor cell survival, proliferation, and invasion.

Purpose of the Study:

  • To review the physiological roles of TSPANs in cancer.
  • To highlight TSPAN1's specific role in acquired chemoresistance.
  • To propose a model for TSPAN1 action and discuss therapeutic targeting.

Main Methods:

  • Literature review of recent studies on TSPANs in cancer.
  • Analysis of TSPAN1's function in tumor cell resistance to chemotherapy.
  • Development of a mechanistic model for TSPAN1's activity.

Main Results:

  • TSPAN1 is crucial for acquired resistance to conventional chemotherapy agents like cisplatin.
  • TSPAN1 influences cell survival, proliferation, and invasion in cancer cells.
  • A model illustrating TSPAN1's mechanism in chemoresistance is proposed.

Conclusions:

  • TSPAN1 is a significant regulator of chemotherapy resistance in cancer.
  • Targeting TSPAN1 presents a promising avenue for novel anticancer therapeutic strategies.
  • Further research into TSPAN family functions in oncology is warranted.
Keywords:
ChemoresistanceMetastasesTSPAN1Tetraspaninscancer

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.8K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.1K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K